Generalized cost-effectiveness analysis: charting a path forward for measuring the societal value of medical technologies.
作者信息
Li Meng
机构信息
Assistant Professor, Center for the Evaluation of Value & Risk in Health, Tufts Medical Center, MA 02111, USA.
出版信息
J Comp Eff Res. 2025 Jan;14(1):e240213. doi: 10.57264/cer-2024-0213. Epub 2024 Nov 26.
Abstract
摘要
相似文献
1
Generalized cost-effectiveness analysis: charting a path forward for measuring the societal value of medical technologies.广义成本效益分析：为衡量医疗技术的社会价值绘制前进道路。
J Comp Eff Res. 2025 Jan;14(1):e240213. doi: 10.57264/cer-2024-0213. Epub 2024 Nov 26.
2
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.重视药品和其他卫生技术的社会影响：当前最佳实践用户指南。
Forum Health Econ Policy. 2024 Nov 8;27(1):29-116. doi: 10.1515/fhep-2024-0014. eCollection 2024 Jun 1.
3
Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements.重构卫生技术评估中的价值难题：一项务实性综述，以确定哪些建模方法能够涵盖额外的价值要素。
Front Pharmacol. 2023 Jul 13;14:1197259. doi: 10.3389/fphar.2023.1197259. eCollection 2023.
4
A review of HTA guidelines on societal and novel value elements.关于 HTA 指南中社会和新颖价值要素的综述。
Int J Technol Assess Health Care. 2023 May 25;39(1):e31. doi: 10.1017/S026646232300017X.
5
Can Generalized Cost-Effectiveness Analysis Leverage Meaningful Use of Novel Value Elements in Pharmacoeconomics to Inform Medicare Drug Price Negotiation?广义成本效益分析能否利用药理学中新颖的价值要素的有意义使用来为医疗保险药品价格谈判提供信息？
Value Health. 2024 Aug;27(8):1100-1107. doi: 10.1016/j.jval.2024.04.013. Epub 2024 Apr 26.
6
Generalized cost-effectiveness analysis to assess treatment value in hepatitis C.用于评估丙型肝炎治疗价值的广义成本效益分析。
Am J Manag Care. 2023 Dec;29(12):696-703. doi: 10.37765/ajmc.2023.89468.
7
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.哪些疾病的更广泛价值要素最重要？对 20 项 ICER 证据报告的评估。
J Manag Care Spec Pharm. 2021 May;27(5):650-659. doi: 10.18553/jmcp.2021.20471. Epub 2021 Mar 29.
8
Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.评估赛来昔布单抗单药治疗中重度活跃类风湿关节炎成人患者的价值：成本效果分析。
J Manag Care Spec Pharm. 2019 Jan;25(1):80-87. doi: 10.18553/jmcp.2019.25.1.080.
9
Incorporating Real Option Value in Valuing Innovation: A Way Forward.将实物期权价值纳入创新估值：一种前进的方式。
Pharmacoeconomics. 2024 Jul;42(Suppl 2):199-210. doi: 10.1007/s40273-024-01352-4. Epub 2024 Feb 4.
10
Approaches to identifying, measuring, and aggregating elements of value.识别、衡量和汇总价值要素的方法。
Int J Technol Assess Health Care. 2013 Oct;29(4):360-4. doi: 10.1017/S0266462313000524.
本文引用的文献
1
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.重视药品和其他卫生技术的社会影响：当前最佳实践用户指南。
Forum Health Econ Policy. 2024 Nov 8;27(1):29-116. doi: 10.1515/fhep-2024-0014. eCollection 2024 Jun 1.
2
Risk preferences over health: Empirical estimates and implications for medical decision-making.对健康的风险偏好：实证估计及其对医疗决策的影响。
J Health Econ. 2024 Mar;94:102857. doi: 10.1016/j.jhealeco.2024.102857. Epub 2024 Jan 9.
3
The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.卫生技术评估的发展变化：对 NICE 新方法手册的批判性评价。
Value Health. 2023 Oct;26(10):1503-1509. doi: 10.1016/j.jval.2023.05.015. Epub 2023 Jun 1.
4
Payer perceptions and use of value assessment tools in the United States.在美国，付款人对价值评估工具的认知和使用。
J Manag Care Spec Pharm. 2023 May;29(5):582-588. doi: 10.18553/jmcp.2023.29.5.582.
5
The half-painted picture: Reviewing the mental health impacts of cancer screening.半成之绘：癌症筛查对心理健康影响的综述。
Medicine (Baltimore). 2022 Sep 23;101(38):e30479. doi: 10.1097/MD.0000000000030479.
6
A Pragmatic Guide to Assessing Real Option Value for Medical Technologies.评估医疗技术实物期权价值的实用指南。
Value Health. 2022 Nov;25(11):1878-1884. doi: 10.1016/j.jval.2022.05.014. Epub 2022 Jun 23.
7
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.在创新治疗领域中对事前临床实物期权价值进行建模：ALK 阳性非小细胞肺癌。
Pharmacoeconomics. 2022 Jun;40(6):623-631. doi: 10.1007/s40273-022-01147-5. Epub 2022 May 9.
8
A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).广义风险调整成本效益评估（GRACE）的扩展和实施指南。
Eur J Health Econ. 2022 Apr;23(3):433-451. doi: 10.1007/s10198-021-01367-0. Epub 2021 Sep 8.
9
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review.药物成本效益分析中使用生产效率损失/增益：系统评价。
Pharmacoeconomics. 2021 Jan;39(1):81-97. doi: 10.1007/s40273-020-00986-4. Epub 2020 Nov 24.
10
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.1974-2018 年成本效益分析中的观点和成本。
Pharmacoeconomics. 2020 Oct;38(10):1135-1145. doi: 10.1007/s40273-020-00942-2.
Zotero 插件